1. Perspectives on sipuleucel-T: Its role in the prostate cancer treatment paradigm.
- Author
-
Gulley, James L., Mulders, Peter, Albers, Peter, Banchereau, Jacques, Bolla, Michel, Pantel, Klaus, and Powles, Thomas
- Subjects
- *
SIPULEUCEL-T (Drug) , *PROSTATE cancer treatment , *IMMUNOTHERAPY , *IMMUNE response , *PROSTATE cancer patients , *THERAPEUTICS - Abstract
Sipuleucel-T is an autologous cellular immunotherapy approved in the US for patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). This significant advance for mCRPC treatment provides healthcare professionals with another effective therapy to extend survival. As an immunotherapy, sipuleucel-T possesses specific characteristics differentiating it from traditional therapies. At a roundtable meeting of experts, sipuleucel-T data were discussed, focusing on interpretation and clinical implications. Important differences between immunotherapies and traditional therapies were explored, e.g., mode of action, outcomes, data consistency and robustness, timing of sipuleucel-T treatment, and future perspectives in areas such as short-term markers of long-term benefit. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF